Frazier Life Sciences Management LP

Search
⚲

Frazier Life Sciences Management LP ✚
CRD #	317522
SEC #	801-122904
CIK #	0001892134
AUM	6,966.9 M (2026-03-31)
Employees	64 (73% Investors, 0% Brokers)
Phone	650-325-5156
Address	1001 Page Mill Road Palo Alto, CA 94304
Source	[IAPD] [EDGAR] [Website] [LinkedIn]

Total AUM ($B) Copy

Sector	Form 13F Holdings	Value ($B)
	Mirum Pharmaceuticals Inc	0.7
	Newamsterdam Pharma Co NV	0.5
	Erasca Inc	0.4
	Bridgebio Pharma Inc	0.3
	Arcutis Biotherapeutics Inc	0.2
	MBX Biosciences Inc	0.2
	Phathom Pharmaceuticals Inc	0.1
	MAZE Therapeutics Inc	0.1
	Krystal Biotech Inc	0.1
	Trevi Therapeutics Inc	0.1
View All

Holdings by Sector ($B)

Type	Form D Funds	Date	Sold	AUM
VC	Frazier Life Sciences XII LP	[2025-03-31]		1,350.6 M
	Filed 2025-03-17 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Not Applicable
HF	Frazier Life Sciences Public Overage Fund LP	[2023-03-31]	243.1 M	362.2 M
	Offered $243,146,976 · Filed 2022-04-14 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Minimum $3,968 · Duration One year or less · Revenue Decline to Disclose
HF	Frazier Life Sciences Public Fund LP	[2022-03-31]		2,868.0 M
	Offered $617,050,000 · Filed 2019-12-17 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $617,050,000 · Duration One year or less · Revenue Not Applicable
VC	Frazier Life Sciences Xi LP	[2022-03-31]	960.0 M	1,107.8 M
	Offered $960,000,000 · Filed 2022-03-18 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Not Applicable
PE	Frazier Life Sciences X LP	[2020-03-30]		781.2 M
	Offered $617,050,000 · Filed 2019-12-17 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $617,050,000 · Duration One year or less · Revenue Not Applicable
VC	Frazier Life Sciences IX LP	[2018-03-30]	418.9 M	596.5 M
	Offered $418,925,000 · Filed 2017-11-01 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Duration One year or less · Revenue Not Applicable
VC	Frazier Life Sciences VIII LP	[2016-03-29]	262.0 M	260.2 M
	Offered $262,000,000 · Filed 2015-10-29 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Minimum $68,750 · Duration One year or less · Revenue Not Applicable

AUM Breakdown	Accounts	AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals)	0	0.0
(b) Individuals (high net worth individuals)	0	0.0
(c) Banking or thrift institutions	0	0.0
(d) Investment companies	0	0.0
(e) Business development companies	0	0.0
(f) Pooled investment vehicles	8	7.0
(g) Pension and profit sharing plans	0	0.0
(h) Charitable organizations	0	0.0
(i) State or municipal government entities	0	0.0
(j) Other investment advisers	0	0.0
(k) Insurance companies	0	0.0
(l) Sovereign wealth funds and foreign official institutions	0	0.0
(m) Corporations or other businesses not listed above	0	0.0
(n) Other	0	0.0
Total	8	7.0
By Discretionary
Discretionary	8	7.0
Non-Discretionary	0	0.0
Total	8	7.0
By Non-United States Persons
Non-United States Persons		0.0
United States Persons		7.0
Total	8	7.0

Form D Directors	Role	# Filings	# Firms
Patrick Heron	Executive Officer	59	3
James Topper	Executive Officer	58	3
Nader Naini	Promoter	43	3
Nathan Every	Promoter	41	3
Steve Bailey	Executive Officer	23	3
Alan Frazier	Promoter	16	3
Daniel Estes	Executive Officer, Promoter	10	2
Frazier Management LLC	Promoter	6	2
Fhmlsp Overage LP	Promoter	2	2
Fhmlsp Overage LLC	Promoter	2	2
View All

EDGAR Form	CIK	2011 - 2026
13F-HR	[0001892134]

Firm Profile (Form ADV)
Serves	Institutional
Fund Types	Hedge Fund, Private Equity
LEI	254900K7JVMHHKW0QH33

Comparable Firms	State	AUM
Arbour Lane Capital Management LP ✚	CT	7,297.3 M
Peak Rock Capital LLC ✚	TX	7,275.0 M
Caspian Capital LP ✚	NY	7,026.2 M
Tilden Park Capital Management LP ✚	NY	6,836.6 M
First Sentier Investors Australia RE Ltd ✚		6,826.5 M
Atairos Management LP ✚	PA	6,786.2 M
Lead Edge Capital Management LLC ✚	NY	6,766.5 M
Discovery Capital Management LLC ✚	CT	6,748.6 M
BC Partners Advisors LP ✚	NY	6,688.9 M
NXT Capital Investment Advisers LLC ✚	IL	6,647.9 M

Frazier Life Sciences Management LP

Assets, Funds, Holdings